Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.
Gopa Iyer, MD, section head, Bladder Cancer, Memorial Sloan Kettering Cancer Center, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.
Although standard-of-care treatments exist for patients with TSC1/2 mutations across different cancer types, these patients may ultimately experience disease progression over time, Iyer explains. Developing a targeted therapy for solid tumors harboring TSC1/2 mutations remains an intriguing avenue for research, Iyer adds.
TSC1/2 mutations are relatively rare among individual tumor types; however, the collective population across different solid tumors represents a meaningful number of patients. A tumor-agnostic targeted therapy would stand to benefit these patients, Iyer adds.
The safety and efficacy of nab-sirolimus (ABI-009) monotherapy is under evaluation in the phase 2 PRECISION 1 trial (NCT05103358), a basket study that is currently enrolling patients with malignant solid tumors harboring pathogenic inactivating TSC1 or TSC2 alterations.